Percheron Therapeutics (ASX:PER) — Material Events
ASX:PER · 8 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Percheron Advances HMBD-002 with Positive Phase I Data and Phase II PlansMedium
Percheron reports positive phase I data for HMBD-002, advances phase II trial plans, and strengthens leadership
31 Oct 2025
·Quarterly Activities Report and Appendix 4C
·85
Percheron Therapeutics Unveils Promising Phase I Data, Sets Stage for Modular Phase II TrialMedium
Percheron Therapeutics reports positive phase I HMBD-002 data, plans modular phase II trial in 2026
30 Jan 2026
·Quarterly Activities Report and Appendix 4C
·85
Percheron Secures Phase II-Ready Cancer Drug, Eyes 2026 TrialsMedium
Percheron licenses phase II-ready cancer drug HMBD-002, plans 2026 trials, reports stable cash runway
31 July 2025
·Quarterly Activities Report and Appendix 4C
·80
Percheron Therapeutics Secures $2.2M to Fuel HMBD-002 Phase II ProgressMedium
Percheron Therapeutics Raises $2.2M to Advance HMBD-002 Phase II Trial
14 Apr 2026
·Capital Raising
·75
Percheron Raises $2.2M as HMBD-002 Advances Toward Phase II TrialMedium
Percheron raises $2.2M, advances HMBD-002 to phase II trial with key conference presentations and manufacturing underway
30 Apr 2026
·Quarterly Activities Report and Appendix 4C
·75
Percheron Therapeutics Reports $14.9M Loss, Shifts Focus to Promising Oncology AssetHigh
Percheron Therapeutics reports $14.9M loss, pivots to oncology with HMBD-002 in-licensing
28 Aug 2025
·Annual Report
·Unexpected
·75
Percheron Therapeutics Cuts Losses, Advances Immuno-Oncology Asset HMBD-002Medium
Percheron Therapeutics halves loss, advances HMBD-002 licensing and phase II trial plans
26 Feb 2026
·Appendix 4D | Half-Year Report
·70
Percheron Therapeutics Launches $2.2M Entitlement Offer to Advance Cancer DrugMedium
Percheron Therapeutics launches $2.2M entitlement offer with free options to fund HMBD-002 development
16 Mar 2026
·Capital Raising
·70
No articles in this tier for the last 12 months.
Market Mentions
4
- appeared in market wrap coverage
These are market wrap articles where Percheron Therapeutics (ASX:PER) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026
18 Apr 2026
Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026
21 Mar 2026
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026